Brain-to-Vein Readiness: How the Oncology Care Team Supports Timely Cellular Therapy Evaluation

In multiple myeloma, the question of whether a patient may be a candidate for CAR T-cell therapy rarely resolves in a single conversation. More often, it emerges across visits: in a response assessment that plateaus, a relapse that arrives earlier than expected, or a patient who asks whether other options exist. Recognizing that moment is a necessary first step, but recognition alone does not move a patient closer to evaluation. The gap between identifying a potential candidate and initiating the evaluation process is where delays most often occur, and where a prepared, coordinated care team can make the greatest difference. 

CAR T-cell therapy requires a window of eligibility that can narrow over time. Performance status, organ function, disease burden, and prior treatment history all influence whether a patient can safely proceed with cellular therapy, and that picture can shift rapidly in multiple myeloma.¹ 

Patients who are heavily pretreated or have accumulated significant treatment-related toxicity may face a narrower eligibility window or longer delays between evaluation and therapy.² Earlier evaluation—before therapy is urgently needed—allows the care team to assess eligibility, initiate required workup, and plan bridging therapy where appropriate, without the additional pressure of a clinical crisis. 

By the time a referral is initiated in response to clinical deterioration, the logistics alone can take weeks. Thus, earlier identification of patients who may be appropriate for a consultation with a treatment center preserves the ability to act when the time is right. 

Referral readiness often starts small: a response assessment that does not look the way the team hoped, a patient who returns sooner than expected, or a note in the chart flagging cellular therapy as a consideration at next relapse.³ 

Practical patterns worth attention include: 

• A patient with known high-risk disease features who is approaching or at second relapse 
• A patient with early progression after transplant or frontline therapy, where the disease trajectory reflects underlying biology 
• A patient who remains functionally well (eg, performance status intact, organ function reasonable) but whose disease is clearly progressing 
• A patient or family member who has asked, “Is there anything else?” 

These factors alone do not determine treatment choice. The most useful care team contribution in these moments is to identify the patient as potentially appropriate for further discussion and bring the question to a multidisciplinary setting before the decision becomes urgent. 

Every treatment center has its own intake process, and requirements vary by institution. However, certain categories of information are consistently important and may take time to gather if the team waits. Proactively organizing these reduces friction at the point of referral.⁴ 

Key documentation categories include: 

• Disease history and prior therapy summary: Dates of diagnosis, lines of therapy, agents received, best responses, and date and nature of last progression. 
• Cytogenetics and molecular data: FISH results, ideally from both diagnosis and most recent relapse. FISH data is frequently incomplete or outdated in referral packets and ensuring the most recent results are accessible before evaluation is one of the highest-value steps a team can take. 
• Performance status and functional assessment: A current ECOG or Karnofsky score, and recent documentation of organ function (renal, hepatic, cardiac). 
• Insurance and authorization status: Preauthorization for a CAR T-cell therapy evaluation visit or for the therapy itself can take weeks. Initiating that process early may prevent delays later.⁴ 
• Patient and caregiver logistics: CAR T-cell therapy typically requires time at or near a treatment center. Understanding the patient’s support system, travel capacity, and caregiver availability early on shapes the planning conversation and helps patients and families begin preparing before urgency arises.³ 

Several barriers recur across practice settings, though most are anticipatable: 

• Ownership ambiguity: In many practices, no one is certain who is responsible for initiating the treatment-center conversation. In these cases, the referral may not happen at all. Practices that manage this well typically designate a specific person to monitor for potential CAR T-cell therapy candidates and ensure the conversation occurs at the right time. 
• Delayed recognition: A patient who should have been flagged at second relapse is instead referred at the fourth or fifth line, when the eligibility picture is considerably narrower. Earlier recognition preserves more options. 
• Insurance and authorization timelines: Payer requirements vary significantly, and prior authorization for cellular therapy can take weeks. Teams that initiate this process early may experience fewer delays later.⁴ 
• Patient and family readiness: CAR T-cell therapy requires a significant commitment from both the patient and their support system. Patients who have not been prepared for this conversation can become hesitant at exactly the moment when speed matters. Introducing the concept early gives patients and families time to process and prepare.³ 

In a shared-care model, the referring or community team continues to manage ongoing myeloma care, maintain the therapeutic relationship, and support the patient through a complex process.⁴ Clear, proactive communication between the referring team and the treatment center can mitigate the risk of critical information falling through the cracks at transition points. 

The shared-care relationship works best when there is a named point of contact on both sides: someone at the referring practice and someone at the treatment center who communicates directly with each other. This requires a relationship and a shared understanding of who is responsible for what. Treatment center coordinators play a particularly important role in this model, and ensuring they are engaged early is one of the highest-value steps a practice can take. 

The clinical proximity of care team members to patients across visits positions them to notice the accumulating signals that may indicate referral readiness.³ Translating that awareness into action means knowing what to watch for, what to gather, and who to contact. 

Proactive documentation reduces logistical burden at the point of evaluation. Early patient and caregiver education about what CAR T-cell therapy involves, and what the process may require, helps families prepare and reduces hesitancy when the conversation becomes clinically relevant. 

The care team’s role in this process is to ensure that the right conversations happen, with the right information, at the right time. That contribution, across every care setting, is what closes the gap. 

• Referral readiness is a team activity. Care team members who know what signals to watch for, what documentation to gather, and who to contact can meaningfully reduce the time between candidate recognition and evaluation. 
• The eligibility window for CAR T-cell therapy can narrow over time. Performance status, organ function, disease burden, and treatment history all factor into candidacy, and earlier evaluation typically preserves more options. 
• Referral-readiness signals often appear before formal progression: a suboptimal response assessment, early relapse, a functionally intact but progressing patient, or a family asking about other options. 
• Most barriers to timely evaluation are anticipatable. Ownership clarity, proactive documentation, early insurance engagement, and patient and family preparation are all addressable before the moment of urgency. 
• Shared care across settings depends on clear communication and named points of contact. 

1. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-567. doi:10.1002/ajh.25791. 
2. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi:10.1038/nrdp.2017.46. 
3. Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management across settings: an ambulatory and community perspective for patients undergoing CAR T–cell therapy in multiple care settings. Clin J Oncol Nurs. 2019;23(2):27-34. 
4. Majhail NS, Mau LW, Chitphakdithai P, Payton T, Eckrich M, Joffe S, et al. National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery. Biol Blood Marrow Transplant. 2012;18(8):1219-1227. doi:10.1016/j.bbmt.2012.01.008.